NYSE : DHR

Danaher Corporation

$191.5 USD

-$1 (-0.52%)

Volume
5.96M
Average Volume
5.01M
Market Capitalization
$134.62B
P/E Ratio
33.89
Dividend Yield
0.75%
Price Target
$225.00
Year High
$242.80
Year Low
$160.93
Day High
—
Day Low
—
Payout Ratio
$0.24
Current Ratio
$1.65
Company Overview

NYSE

Rainer Blair

Medical - Diagnostics & Research

Healthcare

DHR

61000

US

USD

https://www.danaher.com

202 828 0850

235851102

0000313616

Liquidity Metrics

0.51

1.65

1.25

0.54

0.24

Sales & Valuation

$24.57B

5.36

2.57

24.63

7.75

Profitability

$5.04

$3.61B

15.95%

18.97%

7.66%

4.33%

P/E Metrics

33.89

1.74

1.74

Analyst Price Target & Rating

$225.00

$249.00

$195.00

Neutral

3/5

43 Analysts

-14.89%

Financial Health Scores

3.29

6/9

$5.28B

$92.37B

$39.79B

$5B

Key Metrics (TTM)

$156.83B

6.25

24.38

1.65

7.66%

5.03%

2.96%

4.06%

$97.58

108 days

Company Executives
Name Title
Jose-Carlos Gutierrez-Ramos Senior Vice President & Chief Science Officer
Matthew R. McGrew Executive Vice President
Rachel Marie Vatnsdal Olson Vice President of Investor Relations
Rainer Blair President, Chief Executive Officer & Director
Julie Sawyer Montgomery Executive Vice President of Diagnostics Platform
Mitchell Rales Co-Founder & Director
Steven Rales Co-Founder & Chairman
Martin Stumpe Chief Technology & AI Officer
Christopher Paul Riley Executive Vice President of Biotechnology Group & Chief Executive Officer of Cytiva
Matthew E. Gugino Chief Financial Officer & Executive Vice President
Christopher Bouda Vice President & Chief Accounting Officer
Poll Results

No votes yet today — be the first to share your view!

About Danaher Corporation (NYSE:DHR) Stock

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers ... bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.

Bank of Nova Scotia Sells 3,275 Shares of Danaher Corporation $DHR

2026-07-25 04:09:53

Bank of Nova Scotia lessened its stake in shares of Danaher Corporation (NYSE: DHR) by 1.6% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 202,353 shares of the conglomerate's stock after selling 3,275 shares during the period. Bank of Nova Scotia's holdings in Danaher were

Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity

2026-07-24 10:13:38

The company delivered a mixed earnings report, but the sell-off looks like an overreaction.

Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect?

2026-07-22 10:56:14

The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Danaher (DHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Don't Quit on Danaher Stock After Horrific Earnings Reaction

2026-07-22 05:06:00

There's reason to believe the stock can stage a comeback after its worst day in two decades.

Danaher Corporation $DHR Stake Raised by Andra AP fonden

2026-07-22 03:45:55

Andra AP fonden raised its holdings in shares of Danaher Corporation (NYSE: DHR) by 648.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 76,642 shares of the conglomerate's stock after buying an additional 66,405 shares during the period. Andra AP fonden's holdings

Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y

2026-07-21 12:36:04

DHR beats Q2 estimates as Life Sciences posts its strongest quarter in years, prompting the company to raise its 2026 adjusted EPS outlook.

Danaher Q2 Earnings Review: Nothing Exciting For Me To Buy This Dip

2026-07-21 12:20:16

Danaher Corporation delivered Q2 revenue of $6.3B (+5.5% y/y), beating estimates and showing segment growth across Biotechnology, Diagnostics, and Life Sciences. Gross margins declined due to higher cost of sales, but operating margins improved significantly on tight SG&A control and DBS-driven productivity. Management raised full-year EPS guidance slightly, but projected low single-digit revenue growth and a slow recovery, disappointing investors and triggering a 14% share price drop.

Danaher Corporation (DHR) Q2 2026 Earnings Call Transcript

2026-07-21 12:03:59

Danaher Corporation (DHR) Q2 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Danaher Corporation (DHR) stock price?

Danaher Corporation(NYSE:DHR) stock price is $191.5 in the last trading session. During the trading session, DHR stock reached the peak price of $242.8 while $160.93 was the lowest point it dropped to. The percentage change in DHR stock occurred in the recent session was --0.52% while the dollar amount for the price change in DHR stock was -$1.

DHR's industry and sector of operation?

The NYSE listed DHR is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of DHR?

Jose-Carlos Gutierrez-Ramos | Senior Vice President & Chief Science Officer
Matthew R. McGrew | Executive Vice President
Rachel Marie Vatnsdal Olson | Vice President of Investor Relations
Rainer Blair | President, Chief Executive Officer & Director
Julie Sawyer Montgomery | Executive Vice President of Diagnostics Platform

How many employees does DHR have?

Number of DHR employees currently stands at 61000. DHR operates from 2200 Pennsylvania Avenue, NW, Washington, DC 20037-1701, US.

Link for DHR official website?

Official Website of DHR is: https://www.danaher.com

How do I contact DHR?

DHR could be contacted at phone #202 828 0850 and can also be accessed through its website. DHR operates from 2200 Pennsylvania Avenue, NW, Washington, DC 20037-1701, US.

How many shares of DHR are traded daily?

The average number of DHR shares traded daily for last 3 months was 5.01M.

What is the market cap of DHR currently?

The market value of DHR currently stands at $134.62B with its latest stock price at $191.5